Financial results to be released after market
close; Conference call to be conducted at 4:30 pm ET
SARASOTA, Fla., Aug. 9, 2023
/PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a
healthcare services fertility company focused on expanding access
to advanced treatment worldwide with its INVOcell® medical device
and the intravaginal culture ("IVC") procedure it enables, will
report financial results for its second quarter 2023, for the
period ended June 30, 2023, after the
market close on Monday, August 14,
2023. The Company has scheduled a conference call that same
day, Monday, August 14, 2023, at
4:30 pm ET, to review the
results.
Second Quarter 2023 Conference Call Details
Date and Time: Monday, August 14, 2023, at
4:30 pm ET
Call-in Information: Interested parties can access the
conference call by dialing 833-756-0861 or 412-317-5751.
Live Webcast Information: Interested parties can access
the conference call via a live webcast, which is available in the
Investor Relations section of the Company's website at
https://www.invobioscience.com/investors/
or https://app.webinar.net/y0l43MO6o9Z.
Replay: A teleconference replay of the call will be
available through August 21, 2023, at
877-344-7529 or 412-317-0088, replay access code #8863258. A
webcast replay will be available in the Investor Relations section
of the Company's website at
https://www.invobioscience.com/investors/ for 90 days.
About INVO Bioscience
We are a healthcare services fertility company dedicated to
expanding the assisted reproductive technology ("ART") marketplace
by making fertility care accessible and inclusive to people around
the world. Our commercialization strategy is focused on the opening
of dedicated "INVO Centers" offering the INVOcell® and IVC
procedure (with three centers in North
America now operational), the acquisition of US-based,
profitable in vitro fertilization ("IVF") clinics and the sale and
distribution of our technology solution into existing fertility
clinics. Our proprietary technology, INVOcell®, is a revolutionary
medical device that allows fertilization and early embryo
development to take place in vivo within the woman's body. This
treatment solution is the world's first intravaginal culture
technique for the incubation of oocytes and sperm during
fertilization and early embryo development. This technique,
designated as "IVC", provides patients a more natural, intimate,
and more affordable experience in comparison to other ART
treatments. We believe the IVC procedure can deliver comparable
results at a fraction of the cost of traditional IVF and is a
significantly more effective treatment than intrauterine
insemination ("IUI"). For more information, please visit
www.invobio.com.
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties, and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at www.sec.gov. We are under no obligation to (and
expressly disclaim any such obligation to) update or alter our
forward-looking statements, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invo-to-report-second-quarter-2023-financial-results-on-monday-august-14-2023-301897232.html
SOURCE INVO Bioscience, Inc.